NRAS and neoplasm: Graf et al. (2020) reported on 111 patients (51 KRAS mutant versus 60 KRAS wild type), finding no difference in OS between KRAS mutant and wild-type tumours.12 Baratti et al. (2021) recently reported on 152 CRPM patients selected to undergo perioperative systemic chemotherapy and CRS with or without HIPEC.13 No difference was reported in OS in wild-type KRAS/NRAS/BRAF patients compared with patients with KRAS or NRAS mutations and wild-type BRAF (49.7 versus 49.3 months).